VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: Results of the NORTHERN trial

  • D.J. S
  • M.J.B. K
  • D. F
 et al. 
  • 1

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

Despite the promise of proangiogenic gene therapy most clinical trials have failed to show benefit for the primary end point analysis. The NOGA angiogenesis Revascularization Therapy: assessment by RadioNuclide imaging (NORTHERN) trial was a double-blind, placebo-controlled study of intramyocardial vascular endothelial growth factor (VEGF165) gene therapy versus placebo, involving seven sites across Canada, designed to overcome major limitations of previous proangiogenic gene therapy trials. A total of 93 patients with refractory Canadian Cardiovascular Society (CCS) class 3 or 4 anginal symptoms were randomized to receive 2,000 mug of VEGF plasmid DNA or placebo (buffered saline) delivered via the endocardial route using an electroanatomical NOGA guidance catheter. There was no difference between the VEGF-treated and the placebo groups in the primary end point of change in myocardial perfusion from baseline to 3 or 6 months, assessed by single photon emission tomography (SPECT) imaging, although a significant reduction in the ischemic area was seen in both groups. Also, similar improvements in exercise treadmill time and anginal symptoms were seen in the VEGF and the placebo groups at 3 and 6 months, although again there were no differences between these groups. Despite the intramyocardial administration of a high "dose" of plasmid DNA using a percutaneous guidance catheter system, there was no benefit of VEGF gene therapy at 3 or 6 months for any of the end points studied.

Author-supplied keywords

  • *coronary artery disease/dt [Drug Therapy]
  • *gene therapy
  • *heart muscle perfusion
  • *vasculotropin/ae [Adverse Drug Reaction]
  • *vasculotropin/cr [Drug Concentration]
  • *vasculotropin/ct [Clinical Trial]
  • *vasculotropin/dt [Drug Therapy]
  • *vasculotropin/pr [Pharmaceutics] XT - coronary a
  • adult
  • angina pectoris
  • article
  • clinical trial
  • controlled clinical trial
  • controlled study
  • coronary artery disease/dt [Drug Therapy]
  • diabetic retinopathy/si [Side Effect]
  • disease severity
  • dizziness/si [Side Effect]
  • double blind procedure
  • drug blood level
  • drug fatality/si [Side Effect]
  • drug induced headache/si [Side Effect]
  • drug treatment failure
  • electrocardiography
  • female
  • heart infarction/si [Side Effect]
  • heart left ventricle ejection fraction
  • heart muscle ischemia
  • human
  • hypotension/si [Side Effect]
  • inflammation/si [Side Effect]
  • ischemia/si [Side Effect]
  • leukocytosis/si [Side Effect]
  • liver function test
  • major clinical study
  • male
  • musculoskeletal pain/si [Side Effect]
  • neurotoxicity/si [Side Effect]
  • pericardial disease/si [Side Effect]
  • peripheral edema/si [Side Effect]
  • placebo
  • plasmid DNA
  • retina disease/si [Side Effect]
  • retina hemorrhage/si [Side Effect]
  • revascularization
  • side effect/si [Side Effect]
  • single photon emission computer tomography
  • skin toxicity/si [Side Effect]
  • thorax pain/si [Side Effect]

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Stewart D.J.

  • Kutryk M.J.B.

  • Fitchett D.

  • Freeman M.

  • Camack N.

  • Su Y.

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free